Analyst Arthur He CFA of H.C. Wainwright maintained a Buy rating on Satellos Bioscience, retaining the price target of C$1.20.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Arthur He CFA has given his Buy rating due to a combination of factors surrounding Satellos Bioscience’s ongoing clinical developments and financial outlook. The company’s SAT-3247 drug is making steady progress, with the first patient dosed in a follow-up Phase 1b study aimed at evaluating its long-term efficacy in adult Duchenne muscular dystrophy patients. This study is expected to provide significant insights into the drug’s potential benefits, particularly in terms of grip strength and other biomarkers, which could indicate the possibility of a “drug holiday” effect.
Additionally, Satellos is preparing for a Phase 2 pediatric study, with regulatory applications submitted across multiple regions, indicating a strategic expansion into a broader patient demographic. Financially, despite reporting no revenue for 3Q25, the company’s net loss was slightly better than expected, and its cash reserves are projected to support operations into 2027. The valuation of Satellos is supported by a risk-adjusted net present value analysis, leading to a 12-month price target of C$1.20 per share. These factors collectively underpin Arthur He’s confidence in the company’s future prospects, justifying the Buy rating.
He CFA covers the Healthcare sector, focusing on stocks such as Satellos Bioscience, Nektar Therapeutics, and Solid Biosciences. According to TipRanks, He CFA has an average return of 27.0% and a 50.00% success rate on recommended stocks.